Related Industries
Related Practices
Attorneys
View Attorneys
News
View News
Events
View Events
Publications
View Publications
The new deal for clients seeking value and efficiency

• Read More

Venture Capital

Our venture capital lawyers represent regional, national and international venture capital firms investing in early-stage companies across a range of industries, most notably in the software, communications and telecommunications sectors, in therapeutics and medical device opportunities and in the energy sector. We advise venture capital investment professionals on all aspects of portfolio company investment, liquidity events, board and general corporate governance, compliance matters. We regularly provide intellectual property and other due diligence review services, often involving the comprehensive assessment of complex patent portfolios and strategy. We also represent venture capital firms in fund formation and fund-raising efforts, regularly advise institutions making investments in venture capital funds and have negotiated investment terms with scores of venture capital firms located throughout the world. We go to great lengths to immerse ourselves in the flow of early-stage deals, and provide our venture capital firm clients with early access to entrepreneurs and emerging companies. In particular, we have superior access to early-stage opportunities from Ireland and Israel, two countries with technology communities in the vanguard of the pan-European technology sector. Our hallmark is pragmatic business advice coupled with deep experience across the full range of investment and fund formation issues.

Representative Client Work

  • Represented Konarka Technologies in $18 million Series C financing
  • Represented a group of venture capital investors in financing rounds aggregating $21.5 million in early-stage funding for a medical technology company developing an innovative, percutaneous approach for delivering heart valves to treat late-stage aortic stenosis
  • Represented a leading venture capital fund with more than $1.6 billion in committed capital under management and facilitated the fund's first "going-private" transaction with a publicly-traded enterprise
  • Represented a venture capital firm in connection with due diligence analyses related to a number of medical device technologies, including spinal implants, ocular lens implants, vascular grafts, aortic valve replacements and cardiac ablation devices
  • Represented a syndicate of venture capital firms in a series of multi-million dollar bridge financings followed by a $4.4 million financing round and recapitalization for a developer of disposable catheter products for the treatment of cardiovascular disorders using laser energy